Frontage Labs Completes US Phase I Trial for China TCM Company

Frontage Laboratories announced its US facility has finished a Phase I dose-escalation trial of a botanical drug for a China client. The test will be used to support a request for FDA approval of the drug. As Frontage noted, the FDA issued guidelines in 2004 for an approval pathway of botanical drugs. The first product to complete the process did so in 2006. The TCM was administered to 30 healthy volunteers. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});